CFAs: Educational Initiatives for ALK+ Metastatic Non-Son-Small Cell Lung Cancer Therapy (Canada)

Pfizer is inviting eligible Canadian organisations to apply for an independent medical education grant focused on improving long-term management and support for patients with ALK-positive metastatic non-small cell lung cancer receiving tyrosine kinase inhibitor therapy.

The program funds patient-centred, multidisciplinary educational initiatives that address real-world therapy management, caregiver support, and coordination of care, with grants of up to CAD 100,000 for projects lasting up to 18 months.

Overview

Pfizer has launched a competitive independent medical education (IME) grant opportunity to strengthen education and support for patients with ALK-positive metastatic non-small cell lung cancer (NSCLC) who are receiving ALK tyrosine kinase inhibitor (TKI) therapy.

The initiative aims to improve understanding, long-term therapy management, and coordinated care among patients, caregivers, and healthcare professionals, while ensuring all funded activities remain fully independent of Pfizer in design and execution.

Purpose and Scope of the Initiative

The grant focuses on addressing unmet educational needs across the ALK-positive metastatic NSCLC care continuum.

It supports initiatives that enhance real-world treatment management, patient engagement, and multidisciplinary collaboration, without involving clinical research or evaluation of therapeutic efficacy.

Key Focus Areas

Funded projects should address one or more of the following priority areas:

• Patient and caregiver education on long-term safety and prolonged ALK inhibitor therapy

• Management strategies for patients receiving ALK tyrosine kinase inhibitors in metastatic NSCLC

• Development of tools to support patients and caregivers throughout treatment

• Education extending from academic cancer centres to community oncology settings

• Optimisation of care through multidisciplinary team-based approaches

• Collaboration between academic experts and community oncologists to improve therapy management

• Preparing patients and care partners to assess tolerability and manage ALK inhibitor side effects

• Strengthening coordination among pharmacists, nurses, and allied health professionals

Projects should clearly demonstrate how they improve patient understanding, engagement, and continuity of care.

What Types of Projects Are Supported?

The program supports independent educational initiatives, including but not limited to:

• Patient tools that support recognition and reporting of treatment-related adverse events

• Educational materials, toolkits, or digital resources for patients, caregivers, and healthcare teams

• Podcasts or multimedia education for allied health professionals

• Local or regional educational programs promoting multidisciplinary management of ALK-positive disease

All initiatives must focus on education and practice improvement rather than clinical research.

Who Is Eligible to Apply?

Eligible applicants must meet the following criteria:

• Be organisations based in Canada

• Have a mission aligned with healthcare professional education or healthcare system improvement

• Demonstrate experience in delivering educational or patient-centred initiatives

• Show the capacity to manage and execute the project independently

Projects should align with patient-centred care principles and support coordination across care settings.

Funding Amount and Project Duration

The grant program offers:

• Funding of up to CAD 100,000 per project

• Maximum project duration of 18 months

Funding must be used solely for approved educational activities and within the defined project timeline.

Why This Grant Matters

ALK-positive metastatic NSCLC often requires long-term treatment with targeted therapies, making ongoing education and support essential.

This initiative helps:

• Improve patient and caregiver confidence in managing long-term therapy

• Strengthen multidisciplinary collaboration in oncology care

• Bridge gaps between academic and community oncology settings

• Enhance real-world outcomes through better therapy management and patient engagement

By focusing on education rather than product promotion, the program supports sustainable improvements in cancer care delivery.

How to Apply

Organisations should prepare a proposal that clearly outlines the educational need, target audience, and expected outcomes.

A strong application should include:

1. A clear description of the identified knowledge or practice gap

2. Defined educational objectives aligned with the program’s focus areas

3. Description of proposed educational activities and tools

4. Explanation of how the project supports patient-centred and multidisciplinary care

5. A realistic budget within the funding cap and project duration

All projects must remain independent, with full responsibility for design, implementation, and evaluation resting with the grantee.

Tips for a Strong Application

Applicants are encouraged to:

• Focus on real-world challenges in long-term ALK inhibitor management

• Demonstrate clear benefit for patients, caregivers, and healthcare teams

• Emphasise collaboration across disciplines and care settings

• Use measurable outcomes to show educational impact

• Ensure strict independence from any commercial influence

Clarity, relevance, and practical applicability are critical evaluation factors.

Frequently Asked Questions (FAQs)

1. What is the main goal of this Pfizer grant?

The grant aims to improve education and support for long-term management of ALK-positive metastatic NSCLC patients receiving ALK tyrosine kinase inhibitors.

2. Who can apply for this funding?

Canadian-based organisations with a focus on healthcare education or healthcare improvement are eligible to apply.

3. Is clinical research supported under this grant?

No. The program supports independent educational initiatives only and does not fund clinical research or therapeutic efficacy studies.

4. What is the maximum funding available?

Projects may request up to CAD 100,000.

5. How long can funded projects run?

The maximum project duration is 18 months.

6. Can projects involve collaboration with healthcare professionals?

Yes. Multidisciplinary collaboration involving oncologists, pharmacists, nurses, and allied health professionals is strongly encouraged.

7. Must projects remain independent of Pfizer?

Yes. All initiatives must be fully independent in design, implementation, and execution, with responsibility solely with the grantee organisation.

Conclusion

Pfizer’s independent medical education grant offers a valuable opportunity for Canadian organisations to improve long-term care, education, and support for patients with ALK-positive metastatic non-small cell lung cancer.

By strengthening patient engagement, multidisciplinary collaboration, and real-world therapy management, funded projects can make a meaningful contribution to better outcomes and quality of care across the oncology landscape.